Deep Genomics vs PathAI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Deep Genomics employs 100-500 people, while PathAI has 300 employees.

PathAI has raised more in total funding at $255M, compared to Deep Genomics's $180M — a gap of $75M. Combined, the two companies have completed 3 known funding rounds.

Deep Genomics holds the higher Awaira Score at 68/100, compared to PathAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 6-point gap that reflects meaningful differences in scale or traction.

Deep Genomics was founded by Brendan Frey in 2015. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Deep Genomics was founded first in 2015, giving it 1 year of additional market experience. PathAI was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Deep Genomics has approximately 100-500 employees, while PathAI has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Deep Genomics and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.